Information Provided By:
Fly News Breaks for September 21, 2016
TBRA, AGN, ICPT
Sep 21, 2016 | 07:44 EDT
Baird analyst Brian Skorney is positive on the yesterday's merger activity in the NASH space, specifically Allergan's (AGN) offer to buy Tobira Therapeutics (TBRA). Based on the upfront payment to Tobira from Allergan, Skorney said he can't help but question whether Intercept (ICPT) shares are undervalued. Skorney reiterated his Outperform rating on Intercept shares and keeps a $332 price target on the stock.
News For ICPT;AGN;TBRA From the Last 2 Days
There are no results for your query ICPT;AGN;TBRA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.